Literature DB >> 2733251

Ocular manifestations in patients infected with human T-lymphotropic virus type I.

N Ohba1, M Matsumoto, M Sameshima, Y Kabayama, K Nakao, K Unoki, F Uehara, K Kawano, I Maruyama, M Osame.   

Abstract

Ocular manifestations in patients infected with human T-lymphotropic retrovirus type I (HTLV-I) consisted of a wide range of neoplastic, infectious and noninfectious vascular or inflammatory lesions. These disorders were associated with two distinct HTLV-I-induced systemic diseases, ie, adult T-cell leukemia/lymphoma and HTLV-I-associated myelopathy. Five of the 10 cases of adult T-cell leukemia/lymphoma had inflammatory or opportunistic infectious ocular lesions, including cytomegalovirus retinitis or eyelid tumor as part of generalized lymphomas. Four of the 17 cases of HTLV-I-associated myelopathy showed noninfectious lesions such as isolated, transient cotton-wool spots and granulomatous iridocylitis. Twenty-four (26.9%) of 89 cases with various ocular diseases but no HTLV-I-induced systemic disease had antibodies to HTLV-I in the serum. The aqueous humor antibodies to HTLV-I in the seropositive carriers were negative, except one carrier case who showed isolated cotton-wool spots in one eye and massive vitreous opacities in the other eye.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2733251

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  27 in total

1.  Primary Sjögren's syndrome with antibodies to HTLV-I: clinical and laboratory features.

Authors:  K Eguchi; N Matsuoka; H Ida; M Nakashima; M Sakai; S Sakito; A Kawakami; K Terada; H Shimada; Y Kawabe
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

Review 2.  HTLV-I infection in human disease.

Authors:  D J Spalton; F Nicholson
Journal:  Br J Ophthalmol       Date:  1991-03       Impact factor: 4.638

3.  Adult T-cell leukemia presenting with episcleritis and secondary glaucoma.

Authors:  Shinichirou Oono; Takuji Kurimoto; Hidehiro Oku; Osamu Mimura
Journal:  Jpn J Ophthalmol       Date:  2009-01-30       Impact factor: 2.447

4.  Characteristics of endogenous uveitis in Hokkaido, Japan.

Authors:  S Kotake; N Furudate; Y Sasamoto; K Yoshikawa; C Goda; H Matsuda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-01       Impact factor: 3.117

Review 5.  Unilateral conjunctival infiltration of Adult T-cell leukemia/lymphoma. Case report and literature review.

Authors:  Joji Shimono; Shigeki Kaino; Kohei Okada; Kazuo Oshimi; Yusuke Ishida; Tatsuro Takahashi; Takuto Miyagishima; Takanori Teshima
Journal:  J Clin Exp Hematop       Date:  2017

6.  Characteristics of endogenous uveitis in Hokkaido, Japan.

Authors:  S Kotake; N Furudate; Y Sasamoto; K Yoshikawa; C Goda; H Matsuda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-10       Impact factor: 3.117

7.  Adult T-cell leukemia with leukemic cell infiltration in the conjunctiva. A case report.

Authors:  K Takahashi; T Sakuma; S Onoe; T Akasaka; Y Tazawa
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

8.  Clinical features of HTLV-I associated uveitis.

Authors:  K Nakao; N Ohba
Journal:  Br J Ophthalmol       Date:  1993-05       Impact factor: 4.638

9.  Evaluation of commercial HTLV-1 test kits by a standard HTLV-1 serum panel.

Authors:  C Fujiyama; T Fujiyoshi; D Matsumoto; H Tamashiro; S Sonoda
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

10.  Successful treatment of young-onset adult T cell leukemia/lymphoma and preceding chronic refractory eczema and corneal injury by allogeneic hematopoietic stem cell transplantation.

Authors:  Fumiya Miyamura; Shinichi Kako; Hiroko Yamagami; Ken Sato; Miki Sato; Kiriko Terasako; Shun-Ichi Kimura; Hideki Nakasone; Satoko Aoki; Shinya Okuda; Rie Yamazaki; Kumi Oshima; Kentaro Yoshinaga; Takakazu Higuchi; Junji Nishida; Toshio Demitsu; Akihiro Kakehashi; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2009-08-25       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.